While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Northcape Capital’s Wendy Herringer isn’t deterred by the 40 per cent crash in Novo Nordisk and is all in on this waste ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Pharmaceutical giant Novo Nordisk is seeking as much as US$830 million (S$1.1 billion) in damages in an application to a ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...

Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.

Novo Nordisk is seeking as much as US$830 million in damages in a Singapore court, saying it was misled by a local biotech ...